Watch the latest video from our Chief Executive Andrew Newland
Who we areIntroducing the Parsortix® PC1 system - the first medical device to receive FDA clearance for the harvest of intact CTCs
Discover moreOnc-ADaPT laboratories provide specialized circulating tumor cell (CTC) enrichment and analysis services
Discover moreCirculating tumor cells (CTCs) have the potential to impact clinical decision making
Discover moreCatch up with the latest webinars
View webinarsLatest report
Please click the links below to download our Annual and Interim Reports and Financial Statements
Open PDF